null result

  1. Chandelier

    Twelve-month trajectories after inpatient rehabilitation in patients with post-COVID syndrome, 2026, Horst, Kupferschmitt, Köllner et al.

    Twelve-month trajectories after inpatient rehabilitation in patients with post-COVID syndrome Abstract Introduction: Post-COVID syndrome commonly manifests with fatigue, cognitive impairment, and psychological symptoms. Although rehabilitation programs are widely used, evidence on long-term...
  2. forestglip

    Trial Report Personalized cognitive and physical Telerehabilitation in post-COVID-19 condition and ME/CFS: A pilot randomized controlled trial, 2026, Azcue et al

    Personalized cognitive and physical Telerehabilitation in post-COVID-19 condition and ME/CFS: A pilot randomized controlled trial Azcue, N.; Barranco-Cano, C.; Tijero-Merino, B.; Acera, M.; Ayo Mentxakatorre, N.; Sáenz Muñoz, A.; Ruiz López, M.; Fernández-Valle, T.; Gabilondo, I...
  3. Utsikt

    Trial Report Safety & efficacy of intensive task-specific training .. recent spinal cord injury: P3 pragmatic, randomised, assessor-blinded .., 2026, Glinsky et al

    Safety and efficacy of intensive task-specific training in people with recent spinal cord injury: a phase 3, pragmatic, randomised, assessor-blinded, superiority trial Abstract (line breaks added) Background It is widely believed that intensive task-specific training enhances neurological...
  4. SNT Gatchaman

    Receptor-binding autoantibodies are not associated with post-COVID fatigue, 2026, Achleitner et al.

    Receptor-binding autoantibodies are not associated with post-COVID fatigue Achleitner; Dänhardt; Kardashi; Toepfner; de With; Li; Jarzebska; Rodionov; Bornstein; Steenblock Persistent fatigue is a common symptom following SARS-CoV-2 infection, but its underlying mechanisms remain incompletely...
  5. SNT Gatchaman

    Preprint Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial, 2026, Naik, Nacul+

    Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial OBJECTIVES To assess the efficacy and safety of low-dose naltrexone (LDN) for reducing fatigue severity at 16 weeks in persons with post-COVID fatigue syndrome (PCFS). DESIGN Decentralized, randomized, parallel...
  6. Chandelier

    Low-dose prednisolone and B vitamins for post-COVID-19 syndrome in Germany: the PreVitaCOV randomised clinical trial, 2026, Gágyor et al.

    Low-dose prednisolone and B vitamins for post-COVID-19 syndrome in Germany: the PreVitaCOV randomised clinical trial Summary Background Post-COVID-19 syndrome is burdensome and not yet adequately treatable, with persistent symptoms including fatigue, dyspnoea, and cognitive impairment. The...
  7. forestglip

    No evidence of hypercoagulability, altered fibrinolysis, or increased fibrin(ogen) microaggregates in never‐hospitalized long COVID, 2026, Fraser+

    No evidence of hypercoagulability, altered fibrinolysis, or increased fibrin(ogen) microaggregates in never‐hospitalized long COVID Last paragraph In summary, in never-hospitalized patients with specialist-confirmed LC, we found no evidence of persistent prothrombotic activation, impaired...
  8. SNT Gatchaman

    Preprint Resting-State Functional Connectivity and Cognitive Performance in Long COVID: A Randomized Controlled Trial, 2026, O’Connor et al.

    Resting-State Functional Connectivity and Cognitive Performance in Long COVID: A Randomized Controlled Trial David O’Connor; Eric Watson; David L Reich; Fernando Carnavali; Megan Mcveety; Pranav Gwalani; Juan P Wisnivesky; Jacqueline H Becker Cognitive impairment is a prevalent, disabling...
  9. forestglip

    Trial Report Controllable Pulse Parameter Transcranial Magnetic Stimulation in Fibromyalgia: A Randomized Control Study, 2026, Drapeau et al

    Controllable Pulse Parameter Transcranial Magnetic Stimulation in Fibromyalgia: A Randomized Control Study Drapeau, Chloe C; Ahmad, Malaikah; Foglia, Stevie D; Park, Jiyeon; Ramdeo, Karishma R; Adams, Faith C; Atwal, Amandeep; Ma, Jinhui; Maida, Eugene; Shanthanna, Harsha; Nelson, Aimee J...
  10. SNT Gatchaman

    Exploratory clinical and immunological changes following Tixagevimab/Cilgavimab administration in immunodeficient patients…, 2026, Seidel+

    Exploratory clinical and immunological changes following Tixagevimab/Cilgavimab administration in immunodeficient patients with SARS-CoV-2-associated ME/CFS and persistent circulating spike protein Seidel; Anft; Wiemers; Seibert; Bertram; Rosiewicz; Stervbo; Westhoff; Babel BACKGROUND...
  11. SNT Gatchaman

    Effectiveness of tailored individual follow-up vs. standard one-day group course on health-related quality of life in [LC], 2026, Wilson+

    Effectiveness of tailored individual follow-up vs. standard one-day group course on health-related quality of life in patients with post COVID-19 condition: a randomized controlled trial Wilson, Marte; Michalsen, Henriette; Anke, Audny; Pedersen, Synne G; Espinasse, Marina; Langeland, Nina; Cox...
  12. Chandelier

    Effects of specialized pro-resolving mediators and telerehabilitation on fatigue, dyspnea & QOL in LC: the ARACOV-02 … trial, 2026, Carpallo-Porcar+

    Effects of specialized pro-resolving mediators and telerehabilitation on fatigue, dyspnea, and quality of life in post‑COVID‑19 condition: the ARACOV-02 randomized controlled trial Abstract Background Post‑COVID‑19 Condition (PCC) is characterized by persistent multisystem symptoms, with...
  13. Chandelier

    [Abstract] Immunoglobulin Replacement Does Not Correlate With Overall Improvement in Post-Acute Sequelae of COVID-19 Symptoms, 2025, Chong et al.

    Immunoglobulin Replacement Does Not Correlate With Overall Improvement in Post-Acute Sequelae of COVID-19 Symptoms Rationale Immunoglobulin (Ig) replacement therapy is a current treatment for patients with certain immune deficiencies. Multiple pathophysiologic mechanisms have indicated the...
  14. Utsikt

    Trial Report Faecal microbiota transplantation in [IBS] (REFIT2): a randomised, double-blind, placebo-controlled, phase 3 trial, 2026, Johnsen et al

    Faecal microbiota transplantation in irritable bowel syndrome (REFIT2): a randomised, double-blind, placebo-controlled, phase 3 trial Abstract Background Gut microbiota composition might have a role in the pathogenesis of irritable bowel syndrome (IBS), and faecal microbiota transplantation...
  15. Andy

    Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial 2026 Goebel+

    Full title: Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial Background Fibromyalgia is a chronic disorder characterised by widespread pain, fatigue, sleep disturbances, and cognitive dysfunction. Evidence...
  16. SNT Gatchaman

    Nirmatrelvir–ritonavir targeting viral persistence in post-COVID-19 condition long COVID in the USA RECOVER-VITAL…, 2026, Baden+

    Nirmatrelvir–ritonavir targeting viral persistence in post-COVID-19 condition long COVID in the USA RECOVER-VITAL: a randomised, double-blind, placebo-controlled, phase 2 trial Lindsey R Baden + 253 others BACKGROUND Post-acute sequelae of SARS-CoV-2 infection, more commonly known as long...
  17. V

    Symptom Response to Low-Dose Naltrexone in Fibromyalgia: An Exploratory Analysis of the Randomized Placebo-Controlled FINAL Trial, 2026, Nielsen et al

    Symptom Response to Low-Dose Naltrexone in Fibromyalgia: An Exploratory Analysis of the Randomized Placebo-Controlled FINAL Trial Nielsen, Maria Juul; Vaegter, Henrik Bjarke; Bruun, Karin Due Abstract Background: Fibromyalgia (FM) remains difficult to manage due to a highly variable symptom...
  18. SNT Gatchaman

    Impact of immunoadsorption on autoantibodies and physical performance in post-COVID patients […] exploratory study of 18 participants, 2026, Wossidlo+

    Impact of immunoadsorption on autoantibodies and physical performance in post-COVID patients: a prospective exploratory study of 18 participants PURPOSE Autoantibodies against β-adrenergic and muscarinic acetylcholine receptors are said to play a role in the pathophysiology of post-COVID...
  19. forestglip

    Preprint Feasibility and outcomes of crossflow membrane plasmapheresis for long COVID in Suriname: [placebo-controlled DBRCT], 2026, Bihariesingh-Sanchit et al

    Feasibility and outcomes of crossflow membrane plasmapheresis for long COVID in Suriname: a randomized double-blind placebo-controlled pilot trial Background Long COVID is heterogeneous and currently without cure. The disease resembles myalgic encephalomyelitis/chronic fatigue syndrome...
  20. forestglip

    Additional effects of group training and online exercise to a 12-week [...] module on [HRQoL] in [adults] with post COVID-19: [RCT], 2026, Gartemann+

    Additional effects of group training and online exercise to a 12-week online pacing and education module on health-related quality of life in adult patients with post COVID-19: a randomized controlled trial Gartemann, Sophie; Luedtke, Kerstin Abstract This study assessed the effectiveness of a...
Back
Top Bottom